There is evidence of the ability of fullerenol and other fullerene derivatives to inhibit the activity of enzymes that are highly expressed in cancer cells, such as glutathione-S-transferase, tyrosine protein phosphatases, tyrosine kinases, caspases, and metalloproteinases [40,41]. The gene discussed is HPGDS; the disease is cancer.